mpx/CV (amoxicillin 200 + potassium clavulunate 28.5 /5ml) - Hetero H/C
Co-amoxiclav is the British Approved Name for the combination antibiotic containing amoxicillin trihydrate, a β-lactam antibiotic, with potassium clavulanate, a β-lactamase inhibitor. This combination results in an antibiotic with an increased spectrum of action and restored efficacy against amoxicillin-resistant bacteria that produce β-lactamase.
This name, unlike co-trimoxazole, has not been widely adopted internationally and the combination product is usually referred to by various names such as amoxicillin with clavulanic acid or amoxicillin+clavulanate or simply by a trade name such as EXCLAV (by NeoMedD), HECLAV-625 (by Mascot),Twinox (by USV) CLAMP (by FGP), Synermox, Augmentin (by GlaxoSmithKline formerly Beecham),Tormoxin Clav (India) or Clavamel.
Clavulanic acid has a high affinity for and binds to certain β-lactamases that generally inactivate amoxicillin by hydrolyzing its β-lactam ring. Combining clavulanate potassium with amoxicillin extends the antibacterial spectrum of amoxicillin to include many bacteria normally resistant to amoxicillin and other penicillins and cephalosporins.
Distribution
Protein binding: About 25% (Clavulanic acid); about 18% (Amoxicillin). Amoxicillin distributes readily into most body tissues and fluids except the brain and spinal fluid.
Excretion
Half-life after oral admin: 1.3 hours (Amoxicillin); 1 hour (Clavulanic acid). About 50-70% of amoxicillin and 25-40% of clavulanic acid are excreted unchanged in urine during the 1st 6 hours after admin.
